EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study

Tom Holvoet, Marie Truyens, Cara De Galan, Harald Peeters, Francisco Mesonero Gismero iD, Ainara Elorza, Paola Torres, Liv Vandermeulen, Aranzazu Jauregui-Amezaga, Rocio Ferreiro-Iglesias, Yamile Zabana iD, Laia Peries Reverter und 2 weitere

Journal of Clinical Medicine · 09.01.2024 · 13 (2) · 365

DOI: 10.3390/jcm13020365 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Clinical Medicine, online erschienen am 09.01.2024. Verfasst von Tom Holvoet und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Pediatrics, Ghent University, 9000 Ghent, Belgium. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Data on ustekinumab and vedolizumab in the elderly inflammatory bowel disease (IBD) population are limited. The aim of the current study was to assess the safety and effectiveness of both in an elderly real-life population.

Methods

A multicentric retrospective study was performed on IBD patients who started vedolizumab or ustekinumab between 2010 and 2020. Clinical and endoscopic remission rates and (serious) adverse events (AE) were assessed.

Results

A total of 911 IBD patients were included, with 171 (19%) aged above 60 (111 VDZ, 60 UST). Elderly patients treated with vedolizumab or ustekinumab had an increased risk for non-IBD hospitalization (10.5% vs. 5.7%, p = 0.021) and malignancy (2.3% vs. 0.5%, p = 0.045) compared to the younger population. Corticosteroid-free clinical (50% vs. 44%; p = 0.201) and endoscopic remission rates (47.9% vs. 31%, p = 0.07) at 1 year were similar. Comparing vedolizumab to ustekinumab in the elderly population, corticosteroid-free (47.9% vs. 31%, p = 0.061) and endoscopic remission rates (66.7% vs. 64.4%, p = 0.981) were similar. Vedolizumab- and ustekinumab-treated patients had comparable infection rates (13.5% vs. 10.0%, p = 0.504), IBD flare-ups (4.5% vs. 5%, p = 1.000), the occurrence of new EIMs (13.5% vs. 10%, p = 0.504), a risk of intestinal surgery (5.4% vs. 6.7%, p = 0.742), malignancy (1.8% vs. 3.3%, p = 0.613), hospitalization (9.9% vs. 11.7%, p = 0.721), and mortality (0.9% vs. 1.7%, p = 1.000). AE risk was associated only with corticosteroid use.

Conclusions

Ustekinumab and vedolizumab show comparable effectiveness and safety in the elderly IBD population. Elderly IBD patients have an increased risk for non-IBD hospitalizations and malignancy compared to the younger IBD population, with corticosteroid use as the main risk factor.

Schlagwörter

Stichwörter der Autor:innen

IBDelderlysafetyustekinumabvedolizumab

Autor:innen und Institutionen

  • Department of Internal Medicine and Pediatrics, Ghent University, 9000 Ghent, Belgium.
  • Ghent Gut Inflammation Group (GGIG), Ghent University, 9000 Ghent, Belgium.
  • Department of Gastroenterology, VITAZ, 9100 Sint-Niklaas, Belgium.
  • Department of Gastroenterology, UZ Ghent, Corneel Heymanslaan 10, 9000 Ghent, Belgium.
  • VIB Center for Inflammation Research (IRC), Ghent University, 9000 Ghent, Belgium.
  • Department of Gastroenterology, University Hospital Ghent, 9000 Ghent, Belgium.

ORCID-Profile: Francisco Mesonero Gismero, Yamile Zabana, Jeroen Geldof, Triana Lobatón

Zitieren

APA

Holvoet, T., Truyens, M., De Galan, C., Peeters, H., Gismero, F. M., Elorza, A., Torres, P., Vandermeulen, L., Jauregui-Amezaga, A., Ferreiro-Iglesias, R., Zabana, Y., Reverter, L. P., Geldof, J., & Lobatón, T. (2024). Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study. Journal of Clinical Medicine, 13(2), 365. https://doi.org/10.3390/jcm13020365

Vancouver

Holvoet T, Truyens M, De Galan C, Peeters H, Gismero FM, Elorza A, et al. Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study. Journal of Clinical Medicine. 2024;13(2):365. doi:10.3390/jcm13020365

BibTeX
@article{Holvoet2024,
  author = {Holvoet, Tom and Truyens, Marie and De Galan, Cara and Peeters, Harald and Gismero, Francisco Mesonero and Elorza, Ainara and Torres, Paola and Vandermeulen, Liv and Jauregui-Amezaga, Aranzazu and Ferreiro-Iglesias, Rocio and Zabana, Yamile and Reverter, Laia Peries and Geldof, Jeroen and Lobatón, Triana},
  title = {Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {2},
  pages = {365},
  doi = {10.3390/jcm13020365}
}
Kostenlos starten →